Acerus Pharmaceuticals Corporation, a specialty pharmaceutical company, focuses on the development, manufacture, marketing, and distribution of pharmaceutical products for men's and women's health. The company offers Natesto, a nasal gel for testosterone replacement therapy in adult males diagnosed with hypogonadism; Estrace, an oral tablet for the symptomatic relief of menopausal symptoms; and UriVarx, a natural health product that helps reduce symptoms of hyperactive bladder, such as daytime urinary frequency, urgency, and nocturia. It also engages in developing Elegant vaginal moisturizer, which provides comfort to women suffering from vaginal dryness; and Elegant pH, a pH balanced vaginal product; Gynoflor, an ultra-low dose vaginal estrogen combined with a probiotic for the treatment of vaginal atrophy, restoration of vaginal flora, and treatment of certain vaginal infections; and Tefina, a clinical stage product for women with female sexual dysfunction. Acerus Pharmaceuticals Corporation sells products through its salesforce in Canada; and through a network of licensed distributors in the United States and internationally. The company was formerly known as Trimel Pharmaceuticals Corporation and changed its name to Acerus Pharmaceuticals Corporation in September 2015. Acerus Pharmaceuticals Corporation was founded in 2008 and is headquartered in Mississauga, Canada.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone416-679-0771
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$7.38 million
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date5/13/2019 (Estimated)
OptionableNot Optionable
Acerus Pharmaceuticals (OTCMKTS:TRLPF) Frequently Asked Questions
What is Acerus Pharmaceuticals' stock symbol?
Acerus Pharmaceuticals trades on the OTCMKTS under the ticker symbol "TRLPF."
How were Acerus Pharmaceuticals' earnings last quarter?
Acerus Pharmaceuticals Co. (OTCMKTS:TRLPF) announced its quarterly earnings data on Monday, November, 5th. The specialty pharmaceutical company reported ($0.01) earnings per share for the quarter, meeting the Thomson Reuters' consensus estimate of ($0.01). The specialty pharmaceutical company earned $1.58 million during the quarter. Acerus Pharmaceuticals had a negative return on equity of 221.27% and a negative net margin of 254.66%. View Acerus Pharmaceuticals' Earnings History.
When is Acerus Pharmaceuticals' next earnings date?
Has Acerus Pharmaceuticals been receiving favorable news coverage?
Press coverage about TRLPF stock has been trending somewhat negative recently, InfoTrie Sentiment reports. The research group identifies positive and negative news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Acerus Pharmaceuticals earned a media sentiment score of -1.1 on InfoTrie's scale. They also assigned headlines about the specialty pharmaceutical company a news buzz of 2.0 out of 10, indicating that recent news coverage is very unlikely to have an effect on the stock's share price in the near future.
Who are some of Acerus Pharmaceuticals' key competitors?
Some companies that are related to Acerus Pharmaceuticals include SCYNEXIS (SCYX), Neos Therapeutics (NEOS), AVEO Pharmaceuticals (AVEO), Pharmaxis (PXSLY), Acasti Pharma (ACST), Aridis Pharmaceuticals (ARDS), Provention Bio (PRVB), VERONA PHARMA P/S (VRNA), Alimera Sciences (ALIM), Zomedica Pharmaceuticals Corp (NYSEAMERICAN) (ZOM), Elite Pharmaceuticals (ELTP), Sesen Bio (SESN), Processa Pharmaceuticals (PCSA), Ovid Therapeutics (OVID) and Medicure (MCUJF).
What other stocks do shareholders of Acerus Pharmaceuticals own?
Who are Acerus Pharmaceuticals' key executives?
Acerus Pharmaceuticals' management team includes the folowing people:
- Ms. Patricia Symmes, Chief Operating Officer
- Dr. Nathan Bryson, Chief Scientific Officer
- Mr. Philippe Savard, VP, Gen. Counsel & Corp. Sec.
- Mr. Edward Gudaitis, Pres , CEO & Director
- Mr. Robert M. Motz, Chief Financial Officer
How do I buy shares of Acerus Pharmaceuticals?
Shares of TRLPF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Acerus Pharmaceuticals' stock price today?
One share of TRLPF stock can currently be purchased for approximately $0.09.
How big of a company is Acerus Pharmaceuticals?
Acerus Pharmaceuticals has a market capitalization of $21.18 million and generates $7.38 million in revenue each year.
What is Acerus Pharmaceuticals' official website?
How can I contact Acerus Pharmaceuticals?
Acerus Pharmaceuticals' mailing address is 2486 Dunwin Drive, Mississauga A6, L5L 1J9. The specialty pharmaceutical company can be reached via phone at 416-679-0771 or via email at [email protected]
MarketBeat Community Rating for Acerus Pharmaceuticals (OTCMKTS TRLPF)
MarketBeat's community ratings are surveys of what our community members think about Acerus Pharmaceuticals and other stocks. Vote "Outperform" if you believe TRLPF will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TRLPF will underperform the S&P 500 over the long term. You may vote once every thirty days.
